Claro Advisors LLC Sells 384 Shares of Illumina, Inc. (NASDAQ:ILMN)

Claro Advisors LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN) by 17.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,848 shares of the life sciences company’s stock after selling 384 shares during the period. Claro Advisors LLC’s holdings in Illumina were worth $247,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ILMN. Zacks Investment Management acquired a new position in Illumina during the 3rd quarter worth approximately $2,924,000. Freemont Management S.A. acquired a new stake in Illumina in the third quarter valued at approximately $1,565,000. Weybosset Research & Management LLC grew its stake in shares of Illumina by 92.0% during the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after buying an additional 8,650 shares during the last quarter. B. Riley Wealth Advisors Inc. increased its holdings in shares of Illumina by 176.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock worth $749,000 after buying an additional 4,579 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Illumina by 65.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company’s stock valued at $4,278,000 after acquiring an additional 12,986 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on ILMN. Stephens boosted their price objective on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Leerink Partners lifted their target price on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Morgan Stanley reduced their target price on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a report on Monday. Finally, Canaccord Genuity Group raised their price target on shares of Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $165.63.

Illumina Stock Performance

Shares of ILMN stock opened at $136.19 on Thursday. The firm has a 50 day moving average of $140.55 and a 200-day moving average of $133.10. The company has a market cap of $21.60 billion, a price-to-earnings ratio of -13.67 and a beta of 1.11. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same period in the prior year, the firm earned $0.33 earnings per share. Illumina’s revenue was down 3.5% on a year-over-year basis. On average, equities analysts forecast that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.